Physician profile
Sheeja Pullarkat
NPI 1497793384
$252,615.59
in general payments reported to CMS, 2019-2025
6 companies · $39K in 2025
The $39K reported for 2025 was more than what 98% of Anatomic Pathology providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $5,815 · 2021: $21K · 2022: $47K · 2023: $45K · 2024: $65K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $76K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Travel and Lodging: $20K · Consulting Fee: $9,188 · Food and Beverage: $2,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $75,717.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,650.00 |
| Travel and Lodging | $20,078.66 |
| Consulting Fee | $9,188.00 |
| Food and Beverage | $2,351.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $113,851.33 | 2019-2024 | Elzonris |
| Blueprint Medicines Corporation | $107,968.43 | 2021-2025 | Ayvakit |
| Sanofi US Services INC. | $21,104.88 | 2025 | |
| Jazz Pharmaceuticals INC. | $4,480.76 | 2019 | |
| Eusa Pharma (US) LLC | $2,625.00 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $2,585.19 | 2025 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheeja Pullarkat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.